PL3288581T3 - Sposób leczenia nowotworu - Google Patents

Sposób leczenia nowotworu

Info

Publication number
PL3288581T3
PL3288581T3 PL16718705T PL16718705T PL3288581T3 PL 3288581 T3 PL3288581 T3 PL 3288581T3 PL 16718705 T PL16718705 T PL 16718705T PL 16718705 T PL16718705 T PL 16718705T PL 3288581 T3 PL3288581 T3 PL 3288581T3
Authority
PL
Poland
Prior art keywords
treating cancer
cancer
treating
Prior art date
Application number
PL16718705T
Other languages
English (en)
Inventor
Nicholas MCGRANAHAN
Rachel ROSENTHAL
Charles Swanton
Karl PEGGS
Sergio Quezada
Original Assignee
Cancer Research Technology Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1507100.4A external-priority patent/GB201507100D0/en
Priority claimed from GBGB1603663.4A external-priority patent/GB201603663D0/en
Priority claimed from GBGB1603731.9A external-priority patent/GB201603731D0/en
Application filed by Cancer Research Technology Limited filed Critical Cancer Research Technology Limited
Publication of PL3288581T3 publication Critical patent/PL3288581T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464401—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/505—CD4; CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
PL16718705T 2015-04-27 2016-04-27 Sposób leczenia nowotworu PL3288581T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1507100.4A GB201507100D0 (en) 2015-04-27 2015-04-27 Method
GBGB1603663.4A GB201603663D0 (en) 2016-03-02 2016-03-02 Method
GBGB1603731.9A GB201603731D0 (en) 2016-03-03 2016-03-03 Method
EP16718705.3A EP3288581B1 (en) 2015-04-27 2016-04-27 Method for treating cancer
PCT/EP2016/059401 WO2016174085A1 (en) 2015-04-27 2016-04-27 Method for treating cancer

Publications (1)

Publication Number Publication Date
PL3288581T3 true PL3288581T3 (pl) 2021-05-31

Family

ID=55809140

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16718705T PL3288581T3 (pl) 2015-04-27 2016-04-27 Sposób leczenia nowotworu

Country Status (22)

Country Link
US (3) US20180064793A1 (pl)
EP (4) EP3603665A1 (pl)
JP (4) JP6918703B2 (pl)
KR (2) KR102629590B1 (pl)
CN (2) CN117467603A (pl)
AU (2) AU2016256220B2 (pl)
BR (1) BR112017020893A2 (pl)
CA (1) CA2982266A1 (pl)
CL (2) CL2017002728A1 (pl)
DK (1) DK3288581T3 (pl)
ES (1) ES2836273T3 (pl)
HU (1) HUE052106T2 (pl)
IL (2) IL298497A (pl)
MX (1) MX2017013777A (pl)
MY (1) MY189338A (pl)
NZ (1) NZ735882A (pl)
PL (1) PL3288581T3 (pl)
PT (1) PT3288581T (pl)
RU (2) RU2020123735A (pl)
SG (2) SG10202007364RA (pl)
WO (1) WO2016174085A1 (pl)
ZA (1) ZA201706616B (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
EP4299136A3 (en) 2015-12-16 2024-02-14 Gritstone bio, Inc. Neoantigen identification, manufacture, and use
US20170224796A1 (en) 2016-02-05 2017-08-10 Xeme Biopharma Inc. Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
AU2017362418B2 (en) 2016-11-17 2024-05-02 Iovance Biotherapeutics, Inc. Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
CA3045811A1 (en) * 2016-12-01 2018-06-07 Nantomics, Llc Tumor antigenicity processing and presentation
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
CA3051869A1 (en) * 2017-02-07 2018-08-16 Memorial Sloan Kettering Cancer Center Use of immune checkpoint modulators in combination with antigen-specific t cells in adoptive immunotherapy
JP7155470B2 (ja) * 2017-03-31 2022-10-19 エーシーティー ジェノミックス （アイピー） カンパニー リミテッド 免疫原性がん特異的エピトープのためのランク付けシステム
JP7307048B2 (ja) 2017-07-14 2023-07-11 ザ フランシス クリック インスティチュート リミティッド 腫瘍におけるｈｌａアレルの分析及びそれらの使用
AU2018348165A1 (en) 2017-10-10 2020-05-21 Gritstone Bio, Inc. Neoantigen identification using hotspots
EP3714275A4 (en) 2017-11-22 2021-10-27 Gritstone bio, Inc. REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS
WO2020043805A1 (en) * 2018-08-28 2020-03-05 CeCaVa GmbH & Co. KG Methods for ranking and/or selecting tumor-specific neoantigens
EP3618071A1 (en) * 2018-08-28 2020-03-04 CeCaVa GmbH & Co. KG Methods for selecting tumor-specific neoantigens
CN109295097B (zh) * 2018-09-30 2020-09-25 北京鼎成肽源生物技术有限公司 一种mrfft2细胞
CN109337873A (zh) * 2018-09-30 2019-02-15 北京鼎成肽源生物技术有限公司 一种lrff细胞
CN109294997B (zh) * 2018-09-30 2020-09-25 北京鼎成肽源生物技术有限公司 一种lrfft1细胞
CN109485721A (zh) * 2018-11-23 2019-03-19 杜学明 一种获得肿瘤特异性t细胞受体的方法
JP2022516639A (ja) * 2019-01-03 2022-03-01 エヴァクシオン・バイオテック・アクティエセルスカブ ネオエピトープを標的とするワクチン
CN110534156B (zh) * 2019-09-02 2022-06-17 深圳市新合生物医疗科技有限公司 一种提取免疫治疗新抗原的方法及系统
CN110689930B (zh) * 2019-10-18 2021-07-30 北京橡鑫生物科技有限公司 检测tmb的方法及装置
CN114651002A (zh) * 2019-11-07 2022-06-21 武汉华大吉诺因生物科技有限公司 肿瘤特异性多肽序列及其应用
JP2023505726A (ja) * 2019-12-12 2023-02-10 アキレス セラピューティクス ユーケー リミテッド 配列決定のための核酸を得る方法
CA3164986A1 (en) 2019-12-20 2021-06-24 Instil Bio (Uk) Limited Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
US20230235008A1 (en) * 2020-02-14 2023-07-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Novel t cell receptors (tcrs) that react to neoantigens
CN111303268B (zh) * 2020-03-10 2021-08-27 江苏兰恩生物治疗技术研究院有限公司 子宫肌瘤新抗原、其应用和子宫肌瘤疫苗
JP2022024683A (ja) 2020-07-28 2022-02-09 株式会社ミツトヨ 形状測定方法
GB202104715D0 (en) 2021-04-01 2021-05-19 Achilles Therapeutics Uk Ltd Identification of clonal neoantigens and uses thereof
GB202202880D0 (en) 2022-03-02 2022-04-13 Achilles Therapeutics Uk Ltd Methods for peptide synthesis
GB202205135D0 (en) 2022-04-07 2022-05-25 Francis Crick Institute Ltd Analysis of HLA alleles transcriptional deregulation
WO2023194491A1 (en) 2022-04-07 2023-10-12 The Francis Crick Institute Limited Analysis of hla alleles transcriptional deregulation
GB202205147D0 (en) 2022-04-07 2022-05-25 Achilles Therapeutics Uk Ltd Identification of clonal neoantigens and uses thereof
GB202210006D0 (en) 2022-07-07 2022-08-24 Achilles Therapeutics Uk Ltd Analysis of T cell samples
WO2024034622A1 (ja) * 2022-08-08 2024-02-15 北海道公立大学法人 札幌医科大学 対象由来のネオアンチゲンを選択するための方法
GB202213928D0 (en) 2022-09-23 2022-11-09 Achilles Therapeutics Uk Ltd Allele specific expression
CN117535352A (zh) * 2023-10-16 2024-02-09 同济大学 一种筛选具有pole抗原特异性t细胞的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2209633C2 (ru) * 1997-09-19 2003-08-10 Юниверсити Оф Саузерн Калифорниа Т-клеточная вакцина для лечения рассеянного склероза
AU3483001A (en) * 2000-02-04 2001-08-14 Corixa Corp Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2011252795B2 (en) 2010-05-14 2015-09-03 Dana-Farber Cancer Institute, Inc. Compositions and methods of identifying tumor specific neoantigens
NZ730355A (en) * 2011-05-24 2022-10-28 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Individualized vaccines for cancer
MX364370B (es) * 2012-07-12 2019-04-24 Persimmune Inc Vacunas contra el cancer personalizadas y terapias de celulas inmunes adoptivas.
EP2882867A1 (en) * 2012-08-10 2015-06-17 The Broad Institute, Inc. Methods and apparatus for analyzing and quantifying dna alterations in cancer
DK2906684T3 (da) 2012-10-10 2020-09-28 Sangamo Therapeutics Inc T-celle-modificerende forbindelser og anvendelser deraf
EP2983702A2 (en) 2013-04-07 2016-02-17 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
WO2015014375A1 (en) * 2013-07-30 2015-02-05 Biontech Ag Tumor antigens for determining cancer therapy
GB201319446D0 (en) * 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
BR112016014410A2 (pt) * 2013-12-20 2018-02-20 The Broad Institute Inc. terapia de combinação com vacina de neoantígeno
TWI755157B (zh) * 2015-03-17 2022-02-11 德商英麥提克生物技術股份有限公司 用於抗胰臟癌與其他癌症的免疫治療的新穎胜肽及胜肽的組合
GB201516047D0 (en) * 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method

Also Published As

Publication number Publication date
JP2018520637A (ja) 2018-08-02
AU2016256220A1 (en) 2017-10-19
IL254760B1 (en) 2023-01-01
WO2016174085A1 (en) 2016-11-03
RU2020123735A (ru) 2020-07-30
CN117467603A (zh) 2024-01-30
EP3603666A1 (en) 2020-02-05
JP6918703B2 (ja) 2021-08-11
SG10202007364RA (en) 2020-09-29
CA2982266A1 (en) 2016-11-03
JP2022008381A (ja) 2022-01-13
HUE052106T2 (hu) 2021-04-28
ZA201706616B (en) 2021-03-31
NZ735882A (en) 2022-07-29
IL254760A (en) 2017-12-31
SG11201707920YA (en) 2017-11-29
IL298497A (en) 2023-01-01
KR20230125090A (ko) 2023-08-28
CN107750278B (zh) 2023-10-03
MY189338A (en) 2022-02-04
ES2836273T3 (es) 2021-06-24
EP3288581A1 (en) 2018-03-07
RU2770447C2 (ru) 2022-04-18
RU2017134504A (ru) 2019-04-04
AU2016256220B2 (en) 2021-10-21
PT3288581T (pt) 2020-12-04
JP2024001069A (ja) 2024-01-09
EP4137151A1 (en) 2023-02-22
KR102629590B1 (ko) 2024-01-24
US20200000903A1 (en) 2020-01-02
KR20170138560A (ko) 2017-12-15
EP3603665A1 (en) 2020-02-05
JP2020127404A (ja) 2020-08-27
US20180064793A1 (en) 2018-03-08
MX2017013777A (es) 2018-03-27
CL2020001730A1 (es) 2020-11-06
US20200000904A1 (en) 2020-01-02
CL2017002728A1 (es) 2018-06-22
IL254760B2 (en) 2023-05-01
EP3288581B1 (en) 2020-11-11
CN107750278A (zh) 2018-03-02
DK3288581T3 (da) 2021-01-11
AU2021286241A1 (en) 2022-01-06
RU2017134504A3 (pl) 2020-08-12
BR112017020893A2 (pt) 2018-07-10

Similar Documents

Publication Publication Date Title
ZA201706616B (en) Method for treating cancer
HK1251407A1 (zh) 治療癌症的方法
IL304252A (en) Cancer treatment methods
IL289947A (en) A method for treating cancer
IL257691A (en) A method for treating cancer
EP3110509A4 (en) Method for treating cancer
HK1254258A1 (zh) 使用阿吡莫德治療癌症的方法
HK1244217A1 (zh) 用於治療蛋白質病的方法
EP3389634A4 (en) METHOD FOR THE TREATMENT OF CANCER
HK1250944A1 (zh) 用於治療癌症的方法
HK1248135A1 (zh) 用於治療癌症的聯合方法
EP3389652A4 (en) METHODS OF TREATING CANCER
HK1250942A1 (zh) 用於治療癌症的方法
IL246558A0 (en) New methods of cancer treatment
HK1250943A1 (zh) 用於治療癌症的方法
EP3247376A4 (en) Method for treating cancer
SG10201508795XA (en) Method for treating cancer
HK1256371A1 (zh) 用於治療腫瘤的方法